Indoco Remedies Share Price

    NSE
    337
    -1.80 (0.30%)
    INDOCO • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    -2.49%

    3Y Annualised Return

    -3.14%

    5Y Annualised Return

    10.82%

    The current prices are delayed, login or Open Demat Account for live prices.

    Indoco Remedies Stock Performance

    1W Return12.25
    1Y Return-2.53
    Today's Low335
    Prev. Close338.80
    Mkt Cap (Cr.)3,123.98
    1M Return19.35
    3Y Return-7.88
    52-Week High387.55
    Open342.20
    PE Ratio0.00
    6M Return0.68
    Today's High344.95
    52-Week Low190
    Face Value2

    Indoco Remedies Company background

    Founded in: 1947
    Managing director: Aditi Kare Panandikar
    Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbaibased pharmaceutical company focused on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, researchoriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a stateoftheart RD Centre and a CRO facility.Currently, Indoco has a presence in therapeutic segments including antiinfective, anticold preparation, opthalmic, antispasmodic, stomatology, antiinflammatory and antifungal. As per AC Nielsen ORGMARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORGMARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardiovascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher thanaverage industry growth. Currently, Indoco has 4 manufacturing facilities. Two are located in Mumbai and two in Goa, and an RD centre in Mumbai. The solid dosage facility in Goa has been accredited by UKMedicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company.In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98bed facility, including a fourbed ICU, stateoftheart analytical lab and capabilities of eCTD submission. It also has GCP certification from UKMHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Companys dependability to outsource bioequivalence studies. This will not only reduce cost but also ensure timebound outcome of studies and add pace to the Companys existing RD efforts.In December, 2015, the Company incorporated Indoco Remedies Singapore Pte Limited, a 100% subsidiary. The subsidiary will be used for the expansion of the companys ambitious plans to extend its activities in the European and US markets. The company has the following 3 subsidiary companies as on 31 March 2016.i. Xtend Industrial Designers and Engineers Private Limited,ii. Indoco Pharmchem Limited,iii. Indoco Remedies Singapore Pte. Ltd.During the year 201718, the Company (FD) was granted two patents by the Indian Patent Office and one by United States Patents Office for formulation of Olopatadine, Gliclazide, and Brinzolamide respectively. The Company was also granted three patents by Indian Patents Office for manufacturing processes of three APIs, viz., Febuxostat, Rufinamide and Lacosamide.Indocos RD efforts received due recognition with the Best Process Patent Award for the year 20162017 forfive Indian patents granted related to Processforthe preparation of Tapentadol, Process for the preparation of Aminoindane compound, Process for preparation of Pyrazole derivatives, Preparation of phenylacetic acid derivative and Preparation of Substituted 1Himidazo4,5c quinoline. This award was presented at Indian Drug Manufacturers Associations 56th Annual Day celebrations held on 20 January 2018.100% subsidiary known as Indoco Remedies Singapore Pte Ltd. was set up in the Czech Republic effective from April 9, 2019.In August21, Company received GCP GLP Accreditation from the UKMHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Division AnaCipher, located at Hyderabad. The Company launched six new products (SKUs), two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment, Methycal 60 K and three in the subchronic segment, Rexidin SRS, Noxa and Subitral in the domestic market in 2022. In 2023, Company acquired 85% equity stake in the US based FPP Holding Company, LLC for USD 4 million from Contract Pharmacal Corp. (CPC). Warren Remedies Private Limited a wholly owned subsidiary of the Company, was incorporated in 202223 for setting up a unit for manufacturing of pharmaceutical products both formulations as well as Active Pharmaceutical Ingredients (API). The Company acquired 26% equity stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited, representing 8,64,000 equity shares of Rs 10/ each and 5,76,000 equity shares of Rs 10/ each respectively, for setting up Solar Power Plant at Akkalkot, Solapur District, Maharashtra.

    As of 04 Jul, 2025, Indoco Remedies share price is ₹338.6. The stock opened at ₹342.2 and had closed at ₹338.8 the previous day. During today’s trading session, Indoco Remedies share price moved between ₹335.00 and ₹344.95, with an average price for the day of ₹339.98. Over the last 52 weeks, the stock has recorded a low of ₹190.00 and a high of ₹387.55. In terms of performance, Indoco Remedies share price has increased by 0.7% over the past six months and has declined by 2.49% over the last year.

    Read More
    Indoco Remedies SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹64,19,431 (-1.24%)

    Daily SIP of 25,000 would have become 64,19,431 in 1 year with a gain of -80,568 (-1.24%)

    View details of Market Depth

    Indoco Remedies Fundamental

    Market Cap (in crs)

    3,123.98

    Face Value

    2

    Turnover (in lacs)

    277.75

    Key Metrics

    Qtr Change %
    78.24% Gain from 52W Low
    35.9
    Dividend yield 1yr %
    Above industry Median
    0.4

    Indoco Remedies Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Indoco Remedies Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    390.21 Cr
    410.55 Cr
    432.66 Cr
    431.49 Cr
    449.64 Cr
    Indoco Remedies Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1670.37 Cr
    1827.13 Cr
    1670.95 Cr
    1543.08 Cr
    1244.64 Cr
    1109.02 Cr
    Indoco Remedies Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    -41.34 Cr
    -28.4 Cr
    -10.01 Cr
    1.82 Cr
    22.03 Cr
    Indoco Remedies Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    -77.95 Cr
    97 Cr
    142.25 Cr
    154.8 Cr
    93.05 Cr
    24.12 Cr

    Indoco Remedies Result Highlights

    • Indoco Remedies Ltd reported a 9.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.5%.

    • Its expenses for the quarter were down by 1.0% QoQ and up 12.7% YoY.

    • The net profit decreased 177.6% QoQ and decreased 14.6% YoY.

    • The earnings per share (EPS) of Indoco Remedies Ltd stood at 2.4 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Indoco Remedies

    Promoter
    58.9%
    Foreign Institutions
    1.2%
    Mutual Funds
    18.5%
    Domestic Institutions
    18.8%
    Public
    21%
    Promoter
    58.8%
    Foreign Institutions
    1.2%
    Mutual Funds
    18.2%
    Domestic Institutions
    19%
    Public
    21%
    Promoter
    58.8%
    Foreign Institutions
    1.7%
    Mutual Funds
    16.7%
    Domestic Institutions
    18.3%
    Public
    21.3%
    Promoter
    58.8%
    Foreign Institutions
    1.5%
    Mutual Funds
    17%
    Domestic Institutions
    18.7%
    Public
    21.1%
    Promoter
    58.7%
    Foreign Institutions
    1.9%
    Mutual Funds
    17.9%
    Domestic Institutions
    19.4%
    Public
    19.9%
    Promoter
    58.7%
    Foreign Institutions
    1.7%
    Mutual Funds
    18.2%
    Domestic Institutions
    19.5%
    Public
    20%

    Indoco Remedies Technical Analysis

    Moving Averages Analysis
    337
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    326.40
    10Day EMA
    314.20
    12Day EMA
    310.60
    20Day EMA
    299.70
    26Day EMA
    293.50
    50Day EMA
    278.40
    100Day EMA
    272.60
    200Day EMA
    284.00
    5Day SMA
    326.00
    10Day SMA
    308.80
    20Day SMA
    296.50
    30Day SMA
    284.90
    50Day SMA
    268.60
    100Day SMA
    253.00
    150Day SMA
    273.70
    200Day SMA
    288.10
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    38158 Rs
    94550 Rs
    Week Rs
    47247 Rs
    106350 Rs
    Month Rs
    31503 Rs
    66345 Rs
    339.53
    Pivot
    Resistance
    First Resistance
    344.07
    Second Resistance
    349.48
    Third Resistance
    354.02
    Support
    First Support
    334.12
    Second support
    329.58
    Third Support
    324.17
    Relative Strength Index
    80.77
    Money Flow Index
    85.44
    MACD
    17.08
    MACD Signal
    12.82
    Average True Range
    12.79
    Average Directional Index
    42.85
    Rate of Change (21)
    20.99
    Rate of Change (125)
    0.31
    Name
    Holding Percent
    Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund
    4.8
    Quant Mutual Fund - Quant Small Cap Fund
    4.55
    Dsp Healthcare Fund
    3.98
    Franklin India Smaller Companies Fund
    2.2
    Hdfc Value Fund
    1.67
    Tata India Pharma & Healthcare Fund
    1.32

    Indoco Remedies Latest News

    03 JUL 2025 | Thursday

    Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    03 JUL 2025 | Thursday

    Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    03 JUL 2025 | Thursday

    Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    View More

    Indoco Remedies Share Price FAQs

    Indoco Remedies share price is ₹337 in NSE and ₹336.8 in BSE as on 4/7/2025.

    Indoco Remedies share price in the past 1-year return was -2.53. The Indoco Remedies share hit a 1-year low of Rs. 190 and a 1-year high of Rs. 387.55.

    The market cap of Indoco Remedies is Rs. 3123.98 Cr. as of 4/7/2025.

    The PE ratios of Indoco Remedies is 0 as of 4/7/2025.

    The PB ratios of Indoco Remedies is 2.82 as of 4/7/2025

    The Mutual Fund Shareholding in Indoco Remedies was 18.52% at the end of 4/7/2025.

    You can easily buy Indoco Remedies shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Indoco Remedies share price is ₹387.55 and ₹190 as of 4/7/2025.

    Please be aware that Indoco Remedies stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -